Role of taxanes in advanced prostate cancer
View/ Open
Use this link to cite
http://hdl.handle.net/2183/21493Collections
- GI-FENM - Artigos [119]
Metadata
Show full item recordTitle
Role of taxanes in advanced prostate cancerDate
2016-02-08Citation
Cassinello J, Carballido Rodríguez J, Antón Aparicio L. Role of taxanes in advanced prostate cancer. Clin Transl Oncol. 2016; 18(10:): 972-980
Abstract
[Abstract] Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer.
Keywords
Prostate cancer
Docetaxel
Cabazitaxel
Androgen deprivation therapy
AR splice variant
Docetaxel
Cabazitaxel
Androgen deprivation therapy
AR splice variant
Editor version
Rights
The final publication is avaliable at Springer Link
ISSN
1699-048X